Latest research on Erbitux

Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.

Latest findings

The results of continuing clinical trials examining ZD1839 (or IMC-C225) in combination with radiotherapy in multiple human malignancies are eagerly awaited. [source, 2003]
The development of compounds such as IMC-C225, an EGFR monoclonal antibody (Baselga, 2001), or ZD1839 (‘Iressa’), an orally active, selective EGFR TYROSINE kinase inhibitor (Ciardiello and Tortora, 2001), is representative of this new therapeutic strategy for the treatment of cancer. [source, 2002]
In the context of drugs acting upstream to inhibit the initiation of MAPK pathway signal transduction, like IMC-C225 or ZD1839, it is interesting to note that the MAPK pathway can be constitutively activated by ras mutations (Hoshino ). [source, 2002]